August 20, 2014 7:14 PM ET

Biotechnology

Company Overview of Idera Pharmaceuticals, Inc.

Company Overview

Idera Pharmaceuticals, Inc., a clinical stage biotechnology company, is engaged in the discovery and development of novel therapeutics that modulate immune responses through toll-like receptors (TLRs) in the United States. The company’s lead drug candidates in TLR program includes IMO-8400, which is in Phase 1/2 clinical trials for the treatment of various autoimmune diseases, such as moderate to severe plaque psoriasis, polymyositis, dermatomyositis, Waldenström’s macroglobulinemia, and diffuse large B-cell lymphoma; and IMO-9200 that is in preclinical studies that supports the submission of an investigational new drug application to the United States Food and Drug Administration. It is als...

167 Sidney Street

Cambridge, MA 02139

United States

Founded in 1989

18 Employees

Phone:

617-679-5500

Fax:

617-679-5592

Key Executives for Idera Pharmaceuticals, Inc.

Chief Executive Officer
Age: 60
Total Annual Compensation: $823.5K
Chief Financial Officer
Age: 53
Total Annual Compensation: $409.5K
Vice President of Clinical Development
Age: 66
Total Annual Compensation: $390.0K
Vice President of Development Programs & Alliance Management
Age: 60
Total Annual Compensation: $388.7K
Compensation as of Fiscal Year 2013.

Idera Pharmaceuticals, Inc. Key Developments

Idera Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Idera Pharmaceuticals, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, revenues were $38,000 against $29,000 a year ago. Loss from operations was $8,329,000 against $3,567,000 a year ago. Net loss applicable to common stockholders was $8,426,000 or $0.10 per basic and diluted share against $5,621,000 or $0.15 per basic and diluted share a year ago. For the six months, revenues were $41,000 against $36,000 a year ago. Loss from operations was $17,302,000 against $7,415,000 a year ago. Net loss applicable to common stockholders was $17,572,000 or $0.22 per basic and diluted share against $9,707,000 or $0.30 per basic and diluted share a year ago.

Idera Pharmaceuticals, Inc. and The Myositis Association Announce Collaboration for Advance Clinical Development of Novel TLR Antagonist, IMO-8400, for Treatment of Myositis

Idera Pharmaceuticals, Inc. and The Myositis Association announced a collaboration to advance a new potential treatment approach for polymyositis and dermatomyositis known as Toll-like receptor (TLR) antagonism. Under the collaboration, Idera and TMA will develop educational programs and resources for patients and healthcare providers, including interactive online chats, on TLR antagonism and opp ortunities to participate in upcoming clinical research. Idera plans to initiate a clinical trial of its investigational drug candidate IMO-8400, a first-in-class antagonist of TLRs 7, 8 and 9, in polymyositis and dermatomyositis by the end of 2014. Polymyositis and dermatomyositis are devastating, rare inflammatory myopathies that cause inflammation and progressive weakness in muscles. Polymyositis and dermatomyositis patients can develop serious disabilities, including loss of mobility, difficulty breathing and swallowing, and have an increased risk of certain cancers. Dermatomyositis is also accompanied by a purple or red skin rash. There are an estimated 15,000 polymyositis patients and 25,000 dermatomyositis patients in the U.S. alone. Both polymyositis and dermatomyositis have been designated as rare diseases by the U.S. Food and Drug Administration (FDA).

Idera Pharmaceuticals, Inc., Q2 2014 Earnings Call, Aug 12, 2014

Idera Pharmaceuticals, Inc., Q2 2014 Earnings Call, Aug 12, 2014

Similar Private Companies By Industry

Company Name Region
Synlogic, Inc. United States
Icogenex Corporation United States
STEMTIDE Inc. United States
American Gene Technologies International Inc. United States
Perseid Therapeutics LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Idera Pharmaceuticals, Inc., please visit www.iderapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.